Izonsteride
Code | Size | Price |
---|
TAR-T27643-1mg | 1mg | £199.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27643-5mg | 5mg | £392.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27643-10mg | 10mg | £552.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27643-25mg | 25mg | £841.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27643-50mg | 50mg | £1,099.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27643-100mg | 100mg | £1,476.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Izonsteride is a selective and potent inhibitor of the 5α-reductase with dual effects on both the type I and type II isoforms of the enzyme.
CAS:
176975-26-1
Formula:
C24H26N2OS2
Molecular Weight:
422.61
Pathway:
Endocrinology/Hormones|Metabolism
Purity:
0.98
SMILES:
CCc1cccc2sc(Sc3ccc4c(CC[C@H]5N(C)C(=O)CC[C@]45C)c3)nc12
Target:
Reductase
References
1. Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D. Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology. 2004 Jan;63(1):114-9. PubMed PMID: 14751361.
2. Trump DL, Waldstreicher JA, Kolvenbag G, Wissel PS, Neubauer BL. Androgen antagonists: Potential role in prostate cancer prevention. Urology. 2001 Apr;57(4 Suppl 1):64-7. PubMed PMID: 11295597.
3. McNulty AM, Audia JE, Bemis KG, Goode RL, Rocco VP, Neubauer BL. Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5alpha-reductase. J Steroid Biochem Mol Biol. 2000 Jan-Feb;72(1-2):13-21. PubMed PMID: 10731633.